Second Genome is advancing deep drug discovery and biomarker pipelines with Precision Therapeutics and Biomarker programs. Second Genome’s two Precision Therapeutics programs include Immuno-oncology, to turn immune checkpoint inhibitor non-responders to responders, and Gastrointestinal Disorders, to directly improve mucosal healing in gastrointestinal disorders. Also progressing a Biomarker program, Second Genome aims to improve cancer diagnosis and therapy selection. Learn more about our Precision Therapeutics and Biomarkers pipeline.
Second Genome Pipeline
IBD: Inflammatory Bowel Disease (Ulcerative Colitis & Crohn’s).